Developing Collaborative Platforms to Advance Neurotechnology and Its Translation.

Neurotechnological devices are failing to deliver on their therapeutic promise because of the time it takes to translate them from bench to clinic. In this Perspective, we reflect on lessons learned from medical device successes and failures and consider how such lessons might shape a strategic vision for translating neurotechnologies in the future. We articulate how the intentional design and deployment of "scientific platforms," from the technology stack of hardware and software through the supporting ecosystem, could catalyze a new wave of innovation, discovery, and therapy. We also identify specific actions that could promote future neurotechnology roadmaps and industrial-academic-government collaborative activities. We believe that community-supported neurotechnology platforms will prove to be transformational in accelerating ideas from bench to bedside, maximizing scientific discovery and improving patient care.
Competing Interests: Declaration of Interests D.A.B. declares research support from Medtronic and holds a patent in the field of neurotechnology licensed to Blackrock Microsystems. H.E.D. declares no competing interests. P.A.S. declares research support from Medtronic and Boston Scientific. G.A.W. declares interests in Cadence Neuroscience (Licensed technology) and NeuroOne (Licensed technology and holds stock). T.J.D. declares consulting agreements with Cortec Neurotechnology, and Synchron and has stock and research support with Medtronic and Bioinduction. T.J.D. has multiple patents in the field of neurotechnology, all licensed to Medtronic.
(Copyright © 2020 Elsevier Inc. All rights reserved.)